Strain Profile
Save
Escherichia coli MG1655
DEP
MG1655
◔
Human-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Escherichia coli MG1655 is a well-characterized, non-pathogenic K-12 laboratory reference strain used extensively as a model organism in microbiology and biotechnology research. Papers associated with this strain in the literature concern basic science topics such as gut colonization dynamics in animal models, metabolic engineering, CRISPR-based genetic tools, and PFAS compound exposure. MG1655 is a research tool, not a probiotic strain, and has no established health benefit profile for human supplementation. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 71 body-system-tagged papers that concern each system. Research coverage, not measured effect.
+2 more systems
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 14 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+2 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
162 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
IN_VITRO
2026
ANIMAL
2026
IN_VITRO
2025
ANIMAL
2025
IN_VITRO
2025
IN_VITRO
2025
IN_VITRO
2025
IN_VITRO
2024
IN_VITRO
2024
IN_VITRO
2024
ANIMAL
2024
ANIMAL
2023
IN_VITRO
2023
IN_VITRO
2023
IN_VITRO
2023
IN_VITRO
2022
ANIMAL
2021
IN_VITRO
2021
ANIMAL
2020
ANIMAL
Browse all 162 papers →
Investigation of Biofilm Formation and Osmotic Stress Tolerance of Nonmotile E. coli MG1655 in Simulated Microgravity
· Scholarly Commons (Embry–Riddle Aeronautical University)
Inner-membrane transporter genotype shapes susceptibility to non-lytic antimicrobials and bacterial fitness in Escherichia coli
· bioRxiv (Cold Spring Harbor Laboratory)
Short-chain fatty acids activate the glutamate-dependent acid resistance system via the tRNA-modifying Mnm pathway in Escherichia coli
· Journal of Bacteriology
Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy
· Science Advances
A recombineering-based platform for high-throughput genomic editing in Escherichia coli
· Applied and Environmental Microbiology
Collective dynamics of Escherichia coli growth under near-lethal acid stress
· mBio
Host Evolution Improves Genetic Circuit Function in Complex Growth Environments
· ACS Synthetic Biology
Biotechnology meets robotics : development of a knowledge driven biofoundry workflow
· Open MIND
Interaction and Functional Impact of Colorectal Cancer Extracellular Vesicles on Escherichia coli
· Sheffield Hallam University
eLife assessment: Metabolic disruption impairs ribosomal protein levels, resulting in enhanced aminoglycoside tolerance
·
Genetically Designed Living Bacteria with Melanogenesis for Tumor‐Specific Pigmentation and Therapeutic Intervention
· Advanced Science
Inhibition of Microbial Growth and Biofilm Formation in Pure and Mixed Bacterial Samples
· Microorganisms
Engineering Escherichia coli MG1655 for Highly Efficient Biosynthesis of 2′-Fucosyllactose by De Novo GDP-Fucose Pathway
· Journal of Agricultural and Food Chemistry
Improving the Editing Efficiency of CRISPR-Cas9 by Reducing the Generation of Escapers Based on the Surviving Mechanism
· ACS Synthetic Biology
Regulating Cardiolipin Biosynthesis for Efficient Production of Colanic Acid in Escherichia coli
· Journal of Agricultural and Food Chemistry
Toxicity of per- and polyfluoroalkyl substances to microorganisms in confined hydrogel structures
· Journal of Hazardous Materials
Genetically engineered probiotics as catalytic glucose depriver for tumor starvation therapy
· Materials Today Bio
The AcrAB-TolC Efflux Pump Impacts Persistence and Resistance Development in Stationary-Phase Escherichia coli following Delafloxacin Treatment
· Antimicrobial Agents and Chemotherapy
A Colon‐Targeted Oral Probiotics Delivery System Using an Enzyme‐Triggered Fuse‐Like Microcapsule
· Advanced Healthcare Materials
Knockout of a labeled strain of Escherichia coli in the mouse gut using native phages
·
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
PMID 42474318 →Short-chain fatty acids activate the glutamate-dependent acid resistance system via the tRNA-modifying Mnm pathway in Escherichia coli· Journal of Bacteriology · 2026
-
[2]
PMID 25733524 →Escherichia coli EDL933 Requires Gluconeogenic Nutrients To Successfully Colonize the Intestines of Streptomycin-Treated Mice Precolonized with E. coli Nissle 1917· Infection and Immunity · 2015
-
[3]
PMID 19364832 →Precolonized Human Commensal Escherichia coli Strains Serve as a Barrier to E. coli O157:H7 Growth in the Streptomycin-Treated Mouse Intestine· Infection and Immunity · 2009
-
[4]
PMID 17709419 →l-Fucose Stimulates Utilization ofd-Ribose by Escherichia coli MG1655 Δ fucAO and E. coli Nissle 1917 Δ fucAO Mutants in the Mouse Intestine and in M9 Minimal Medium· Infection and Immunity · 2007